A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Type of Cancer
Lung

Sponsor
Merck

Protocol Number
MK-3475-654

To Learn More Call
(201)-510-0950